Pfizer And LianBio Collaborate to Expand the Development of Novel Therapeutics in Greater China
Shots:
- Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development- regulatory and commercial expertise
- Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion- products will be presented to Pfizer for joint development
- Pfizer will have a right of first negotiation to obtain commercial rights to jointly developed assets & each company will carry separate financial considerations. Additionally- Pfizer may provide in-kind support for marketing- development & regulatory activities
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
